These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12115204)

  • 21. Membranous nephropathy in rheumatoid arthritis: a case report.
    Maruotti N; Corrado A; Gaudio A; Cantatore FP
    Clin Exp Rheumatol; 2009; 27(5):840-2. PubMed ID: 19917171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis.
    Hooper DR; Tarnopolsky MA; Baker SK
    Muscle Nerve; 2008 Oct; 38(4):1318-25. PubMed ID: 18671292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An alternative, autonomic rationale for decreased risk of myocardial infarction in patients with rheumatoid arthritis responsive to anti-tumor necrosis factor therapy: comment on the article by Dixon et al.
    Holman AJ
    Arthritis Rheum; 2008 Jun; 58(6):1886; author reply 1886. PubMed ID: 18512805
    [No Abstract]   [Full Text] [Related]  

  • 25. Nerve growth factor and brain-derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers.
    del Porto F; Aloe L; Laganà B; Triaca V; Nofroni I; D'Amelio R
    Ann N Y Acad Sci; 2006 Jun; 1069():438-43. PubMed ID: 16855171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Apperceptive form visual agnosia caused by anti-TNFalpha therapy to rheumatoid arthritis].
    Kobayashi S; Tanno M; Nakamura I; Ito K; Ugawa Y
    Rinsho Shinkeigaku; 2007; 47(2-3):96-9. PubMed ID: 17511276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.
    Wolfe F; Michaud K
    J Rheumatol; 2004 Nov; 31(11):2115-20. PubMed ID: 15517621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-TNFalpha therapy for rheumatoid arthritis: an update.
    Taylor PC
    Intern Med; 2003 Jan; 42(1):15-20. PubMed ID: 12583612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disseminated primary varicella infection during infliximab treatment.
    Vonkeman H; ten Napel C; Rasker H; van de Laar M
    J Rheumatol; 2004 Dec; 31(12):2517-8. PubMed ID: 15570661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Significance of tumor necrosis factor (TNF-alpha) in rheumatoid arthritis].
    Godyń-Swedzioł RM; Stańczyk J; Hilt J; Kowalski ML
    Przegl Lek; 2004; 61(2):90-3. PubMed ID: 15230148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis.
    Lassoued S; Zabraniecki L; Marin F; Billey T
    Semin Arthritis Rheum; 2007 Feb; 36(4):262-3. PubMed ID: 17067660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.
    Kavanaugh AF
    Rheum Dis Clin North Am; 1998 Aug; 24(3):593-614. PubMed ID: 9710889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F; Michaud K
    Am J Med; 2004 Mar; 116(5):305-11. PubMed ID: 14984815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [B-cell depletion in the treatment of rheumatoid arthritis].
    Feist E; Burmester GR; Dörner T
    Z Rheumatol; 2003 Aug; 62(4):361-6. PubMed ID: 12928940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 37. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis.
    Geraghty EM; Ristow B; Gordon SM; Aronowitz P
    Clin Infect Dis; 2007 May; 44(10):e82-4. PubMed ID: 17443458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Schiff MH
    Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
    [No Abstract]   [Full Text] [Related]  

  • 39. Association of inflammatory mediators with premature atherosclerosis in rheumatoid arthritis and healthy controls: comment on the article by Rho et al.
    Welsh P; Sattar N; Peters M
    Arthritis Care Res (Hoboken); 2010 Jul; 62(7):1052-3; author reply 1053-4. PubMed ID: 20589689
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.